163 related articles for article (PubMed ID: 38469156)
1. Differences in management approaches for lupus nephritis within the UK.
Ibrahim ST; Edwards CJ; Ehrenstein MR; Griffiths B; Gordon C; Hewins P; Jayne D; Lightstone L; McLaren Z; Rhodes B; Vital EM; Reynolds JA
Rheumatol Adv Pract; 2024; 8(1):rkae017. PubMed ID: 38469156
[TBL] [Abstract][Full Text] [Related]
2. Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE.
Gilbert M; Goilav B; Hsu JJ; Nietert PJ; Meidan E; Chua A; Ardoin SP; Wenderfer SE; von Scheven E; Ruth NM;
Pediatr Rheumatol Online J; 2021 Aug; 19(1):137. PubMed ID: 34461932
[TBL] [Abstract][Full Text] [Related]
3. Working Towards a Treat-to-Target Protocol in Juvenile Proliferative Lupus Nephritis - A Survey of Pediatric Rheumatologists and Nephrologists in Germany and Austria.
Vollbach K; Schuetz C; Hedrich CM; Speth F; Mönkemöller K; Brunner J; Neudorf U; Rietschel C; Hospach A; Kallinich T; Hinze C; Wagner N; Tönshoff B; Weber LT; Latta K; Thumfart J; Bald M; Wiemann D; Zappel H; Tenbrock K; Haffner D
Front Pediatr; 2022; 10():851998. PubMed ID: 35529329
[TBL] [Abstract][Full Text] [Related]
4. Rituximab use as induction therapy for lupus nephritis: a systematic review.
Stolyar L; Lahita RG; Panush RS
Lupus; 2020 Jul; 29(8):892-912. PubMed ID: 32486934
[TBL] [Abstract][Full Text] [Related]
5. Practice Patterns and Approach to Childhood Lupus Nephritis in Saudi Arabia.
AlMutairi A; Al-Mayouf SM; Kari J; Basahl E; Nashawi M
Saudi J Kidney Dis Transpl; 2023 Nov; 34(6):576-591. PubMed ID: 38725208
[TBL] [Abstract][Full Text] [Related]
6. Use of EuroLupus Cyclophosphamide Dosing for the Treatment of Lupus Nephritis in Childhood-onset Systemic Lupus Erythematosus in North America.
Cannon LA; Wenderfer SE; Lewandowski LB; Cooper JC; Goilav B; Knight AM; Hersh AO; Ardoin SP; Sadun RE;
J Rheumatol; 2022 Jun; 49(6):607-614. PubMed ID: 35169053
[TBL] [Abstract][Full Text] [Related]
7. Refractory lupus nephritis: a survey.
Weidenbusch M; Bai Y; Eder J; Anders HJ;
Lupus; 2019 Apr; 28(4):455-464. PubMed ID: 30755142
[TBL] [Abstract][Full Text] [Related]
8. Multidisciplinary approach to lupus nephritis: Clinical pearls, pitfalls, and positioning of newly-approved agents.
Fanouriakis A; Bertsias G; Liapis G; Marinaki S; Papagianni A; Stangou M; Garyfallos A; Lionaki S; Tektonidou MG; Boletis JN; Boumpas DT
Lupus; 2023 Sep; 32(10):1155-1163. PubMed ID: 37499240
[TBL] [Abstract][Full Text] [Related]
9. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study.
Moroni G; Raffiotta F; Trezzi B; Giglio E; Mezzina N; Del Papa N; Meroni P; Messa P; Sinico AR
Rheumatology (Oxford); 2014 Sep; 53(9):1570-7. PubMed ID: 24505125
[TBL] [Abstract][Full Text] [Related]
10. Lupus Nephritis in Asia: Clinical Features and Management.
Yap DY; Chan TM
Kidney Dis (Basel); 2015 Sep; 1(2):100-9. PubMed ID: 27536670
[TBL] [Abstract][Full Text] [Related]
11. Approach to Membranous Lupus Nephritis: A Survey of Pediatric Nephrologists and Pediatric Rheumatologists.
Boneparth A; Radhakrishna SM; Greenbaum LA; Yen E; Okamura DM; Cooper JC; Mason S; Levy DM; Sule SD; Jensen PT; Yildirim-Toruner C; Ardoin SP; Wenderfer SE
J Rheumatol; 2017 Nov; 44(11):1619-1623. PubMed ID: 28916546
[TBL] [Abstract][Full Text] [Related]
12. Induction therapy for pediatric onset class IV lupus nephritis: Mycophenolate Mofetil versus Cyclophosphamide.
Chbihi M; Eveillard LA; Riller Q; Brousse R; Berthaud R; Quartier P; Salomon R; Charbit M; Avramescu M; Biebuyck N; Dehoux L; Garcelon N; Duong-Van-Huyen JP; Bader-Meunier B; Boyer O
J Nephrol; 2023 Apr; 36(3):829-839. PubMed ID: 36208405
[TBL] [Abstract][Full Text] [Related]
13. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis.
Fanouriakis A; Kostopoulou M; Cheema K; Anders HJ; Aringer M; Bajema I; Boletis J; Frangou E; Houssiau FA; Hollis J; Karras A; Marchiori F; Marks SD; Moroni G; Mosca M; Parodis I; Praga M; Schneider M; Smolen JS; Tesar V; Trachana M; van Vollenhoven RF; Voskuyl AE; Teng YKO; van Leew B; Bertsias G; Jayne D; Boumpas DT
Ann Rheum Dis; 2020 Jun; 79(6):713-723. PubMed ID: 32220834
[TBL] [Abstract][Full Text] [Related]
14. Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations.
Kostopoulou M; Fanouriakis A; Cheema K; Boletis J; Bertsias G; Jayne D; Boumpas DT
RMD Open; 2020 Jul; 6(2):. PubMed ID: 32699043
[TBL] [Abstract][Full Text] [Related]
15. Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis.
Davies RJ; Sangle SR; Jordan NP; Aslam L; Lewis MJ; Wedgwood R; D'Cruz DP
Lupus; 2013 May; 22(6):574-82. PubMed ID: 23632989
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis.
Basu B; Roy B; Babu BG
Pediatr Nephrol; 2017 Jun; 32(6):1013-1021. PubMed ID: 28191596
[TBL] [Abstract][Full Text] [Related]
17. Lupus Nephritis: A Different Disease in European Patients?
Tesar V; Hruskova Z
Kidney Dis (Basel); 2015 Sep; 1(2):110-8. PubMed ID: 27536671
[TBL] [Abstract][Full Text] [Related]
18. A Prospective Study on Long-Term Clinical Outcomes of Patients With Lupus Nephritis Treated With an Intensified B-Cell Depletion Protocol Without Maintenance Therapy.
Roccatello D; Sciascia S; Naretto C; Alpa M; Fenoglio R; Ferro M; Quattrocchio G; Rubini E; Rahbani E; Rossi D
Kidney Int Rep; 2021 Apr; 6(4):1081-1087. PubMed ID: 33912758
[TBL] [Abstract][Full Text] [Related]
19. Multitarget therapy of mycophenolate mofetil and cyclosporine A for induction treatment of refractory lupus nephritis.
Jesus D; Rodrigues M; da Silva JAP; Inês L
Lupus; 2018 Jul; 27(8):1358-1362. PubMed ID: 29448882
[TBL] [Abstract][Full Text] [Related]
20. Resorption of immune deposits in membranous lupus nephritis following rituximab vs conventional immunosuppressive treatment.
Zickert A; Lannfelt K; Schmidt Mende J; Sundelin B; Gunnarsson I
Rheumatology (Oxford); 2021 Jul; 60(7):3443-3450. PubMed ID: 33367774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
